Chart Of The Day: Moderna Set For Explosive Move (But Not Yet Clear Which Way)

 | Jan 20, 2021 22:47

Saying that Moderna (NASDAQ:MRNA) was the best performing COVID-19 vaccine stock in the past year would be a laughable understatement. Shares of  AstraZeneca (NASDAQ:AZN) gained 0.25% for the period; Pfizer (NYSE:PFE) added 3.1% of value. But Moderna blew past all of them, rising 687%.

Yesterday, we noted that Pfizer’s technical chart suggests a selloff could be in the cards. Today we'll be providing both bullish and bearish setups for Moderna since the biotech stock has reached an inflection point based on its technicals.

But perhaps the key fundamental question is why Moderna shares have so overwhelmingly outperformed the competition?

The efficacy numbers tell the story. Moderna's vaccine demonstrated 95% effectiveness in prevention of coronavirus and was 100% effective when used to combat severe cases of the virus.

Based on those results, 30 countries approved the use of Moderna's vaccine. The Cambridge, Massachusetts-based company has already earned $2.89 billion and is expected to receive another $11.7 billion this year from this vaccine alone. But that’s only the beginning.

The biotech is now running clinical trials in order to expand the use of its vaccine to young children and adolescents. It's also testing a booster shot for adults, with which to extend the efficacy of the immunization. If successful, this could also mean additional, guaranteed revenue on an annual basis.